ProKidney Updates Phase 3 Trial Enrollment and Confirmatory Data Readout to 2H 2029
PROK has more than doubled off its 52-week low of $0.46 on light trading volume (0.4× avg).
Summary
ProKidney updated its Phase 3 PROACT 1 trial, increasing the total enrollment target to 470 subjects and setting the confirmatory endpoint data readout for the second half of 2029, while the accelerated approval timeline remains Q2 2027.
Key Events · Product Development and Regulatory · PROK
-
Phase 3 Enrollment Target Increased
The total target enrollment for the Phase 3 REGEN-006 (PROACT 1) study has been updated to approximately 470 subjects.
-
Confirmatory Endpoint Timeline Extended
Topline data readout for the confirmatory endpoint (composite time-to-event) is now anticipated in the second half of 2029.
-
Accelerated Approval Timeline Unchanged
The topline data readout for the surrogate endpoint (eGFR slope) for accelerated approval remains on track for Q2 2027.
Analysis · PROK · Life Sciences
ProKidney Corp. has updated its investor presentation, providing new details on its pivotal Phase 3 REGEN-006 (PROACT 1) study. While the topline data readout for the surrogate endpoint (eGFR slope) for accelerated approval remains on track for Q2 2027, the company now anticipates the topline data readout for the confirmatory endpoint (composite time-to-event) in the second half of 2029. This extends the timeline for full regulatory approval. The total target enrollment for the study has also been updated to approximately 470 subjects, an increase from the ~360 subjects previously targeted for the accelerated approval efficacy analysis. This update provides a clearer, albeit longer, timeline for the full clinical development of rilparencel.
At the time of this filing, PROK was trading at $2.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $613.7M. The 52-week trading range was $0.46 to $7.13. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.